Mrs. Jennifer Cotman Walker, AUD Audiologist Medicare: Not Enrolled in Medicare Practice Location: 3017 13th St, Gulfport, MS 39501 Phone: 228-863-6617 Fax: 228-863-1747 |
Mrs. Charlene M Taylor, AU.D. Audiologist Medicare: Accepting Medicare Assignments Practice Location: 3017 13th St, Gulfport, MS 39501 Phone: 228-863-6592 Fax: 228-863-1747 |
Mrs. Melissa Kirkwood Rounsaville Audiologist Medicare: Accepting Medicare Assignments Practice Location: 3017 13th St, Gulfport, MS 39501 Phone: 228-863-6592 Fax: 228-863-1747 |
Mrs. Nicole Scairono Merrill, AU.D. Audiologist Medicare: Accepting Medicare Assignments Practice Location: 15190 Community Rd, Suite 100, Gulfport, MS 39503 Phone: 228-539-3824 Fax: 228-539-1572 |
Amanda Hammon Guillotte, AU.D. Audiologist Medicare: Accepting Medicare Assignments Practice Location: 3017 13th St, Gulfport, MS 39501 Phone: 228-863-6592 |
Malendia Eads Taylor, AUD Audiologist Medicare: Accepting Medicare Assignments Practice Location: 3017 13th St, Gulfport, MS 39501 Phone: 228-863-6592 |
Kathryn Jade White Garrard, AUD-CCCA Audiologist Medicare: Not Enrolled in Medicare Practice Location: 3017 13th St, Gulfport, MS 39501 Phone: 228-863-6592 |
Karen Keel Williams, AUD Audiologist Medicare: Accepting Medicare Assignments Practice Location: 9000 Lorraine Rd, Gulfport, MS 39503 Phone: 228-864-2121 Fax: 228-678-0950 |
Mrs. Karen Elizabeth Slater, AU.D. Audiologist Medicare: Accepting Medicare Assignments Practice Location: 3017 13th Street, Gulfport, MS 39501 Phone: 228-863-6592 Fax: 228-863-6617 |
News Archive
A.P. Pharma, Inc., a specialty pharmaceutical company, today announced that, on May 18, 2010, the Company received a letter from The Nasdaq Stock Market (Nasdaq) indicating that the minimum closing bid price of its common stock had fallen below $1.00 for 30 consecutive trading days, and therefore, A.P. Pharma was not in compliance with Marketplace Rule 5550(a)(2).
Investigators failed to see improvement in colorectal cancer (CRC) screening rates among patients enrolled in a managed care health plan after testing the effectiveness of a CRC screening promotion program targeting the physician organizations (POs).
A new study might explain why humans register some tastes more quickly than others, potentially due to each flavor's molecular size.
Archivel Farma, S.L. has announced that its breakthrough treatment for tuberculosis (TB) will shortly start phase II clinical trials. The treatment uses the company's unique combination of its novel therapeutic vaccine called RUTIĀ® in conjunction with an antibiotic. This cuts treatment time from nine months to one month, which reduces side effects and healthcare costs, by preventing re-infection during the eradication process. The company expects commercial availability in 2015.
› Verified 8 days ago